CASE STUDY

INTEGRA® LIMIT UNCERTAINTY

PRODUCTS

MicroMatrix® UBM Particulate

Cytal® Wound Matrix

MicroMatrix® UBM Particulate and Cytal® Wound Matrix 6-Layer Devices Facilitate Closure of Severe Scalp Degloving Wound

Catherine Ronaghan, MD, at University Medical Center in Lubbock, Texas

Case Information

Age: 27 | **Sex:** Male

Integra® LifeSciences Products Used:

- MicroMatrix® UBM Particulate
- Cytal® Wound Matrix 6-Layer

Case Outcome

Following management with MicroMatrix and Cytal, patient was discharged at 23 hours and wound closed on post-op day 48. The patient was not readmitted.

Before MicroMatrix & Cytal Application



Figure 1. Patient presents with 8 cm x 9 cm full-thickness wound of the forehead and scalp following a motor vehicle accident.

After MicroMatrix & Cytal Application



Figure 2. Post-application Day 61; continuous remodeling.

Case Presentation and Background

A 27-year-old male patient presented with a full-thickness degloving wound to the forehead following an unrestrained motor vehicle accident. The injury measured approximately 72 cm^2. The patient was triaged at a community hospital and subsequently transferred to a Level 1 trauma center for management.



Figure 3. Wound is managed with 500 mg of MicroMatrix UBM Particulate and one 7 cm x 10 cm Cytal Wound Matrix 6-Layer device.

Wound Management

The wound was cleaned and MicroMatrix UBM Particulate and Cytal Wound Matrix 6-Layer devices were applied bedside. No operative intervention was conducted. The wound was dressed with a non-adherent dressing, hydrogel, a bulky gauze bandage, and an occlusive outer layer. Patient was discharged at 23 hours.



Figure 4. Post-application Day 20.

Clinical Outcomes and Follow-Up

Following discharge, the dressings were retained until the first patient follow-up visit at day 20. Neither home healthcare nor concomitant wound therapies (e.g. Negative Pressure Wound Therapy) were utilized. Without further Integra product usage or autologous skin grafting, the patient went on to achieve full wound closure by day 48.

Case Summary

500 mg of MicroMatrix UBM Particulate and one 7 cm x 10 cm Cytal Wound Matrix 6-Layer device were applied to cover the full-thickness wound following a light, non-operative debridement. There were no subsequent applications of Integra wound products.

Why Did You Choose These Integra Products

Upon assessment by the treating physician, it was determined that a rotational flap, free flap, or negative pressure therapy may be too invasive for wound management due to location of injury. Application of MicroMatrix and Cytal wound products allowed the treating physician to manage the wound bedside with minimal follow-up required.

Source

This case was managed by Catherine Ronaghan, MD, at University Medical Center in Lubbock, Texas. Dr. Ronaghan is a board-certified general surgeon and surgical oncologist.



Figure 5. Post-application Day 34.



Figure 6. Post-application Day 48; epithelialization evident.



Figure 7. Post-application Day 61; continuous remodeling.

Dr. Ronaghan was a paid consultant to ACell®, Inc., which was acquired by Integra LifeSciences in 2021. The results presented herein are case-specific and should not be used to draw general conclusions as to clinical outcomes.

MicroMatrix® UBM Particulate

INDICATIONS

MicroMatrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. This device is intended for one-time use.

CONTRAINDICATIONS

1. Known sensitivity or allergy to porcine materials.
2. Third-degree burns.

WARNINGS

1. If active infection is present, treat patient to resolve infection prior to device application.
2. Do not use glass vial if cracked, broken, or otherwise damaged.
3. MicroMatrix is not indicated for treatment of alopecia.

PRECAUTIONS

Do not tap glass vial with metal objects or handle in a way that may cause glass to break and contaminate wound.

Cytal® Wound Matrix

INDICATIONS

Cytal Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.

CONTRAINDICATIONS

1. Patients with known sensitivity or allergy to porcine materials.
2. Third-degree burns.

WARNINGS

1. Exposure to contaminated or infected field can lead to rapid breakdown of device.
2. If active infection is present, treat patient to resolve infection prior to device application.
3. Do not use if cracked, broken, or otherwise damaged.

PRECAUTIONS

Always use aseptic technique when handling device.

For more information or to place an order, please contact:
United States, Canada, Asia, Pacific, Latin America

USA 800-654-2873 ▪ 888-980-7742 fax
International +1 609-936-5400 ▪ +1 609-750-4259 fax
integralife.com

INTEGRA®
LIMIT UNCERTAINTY